Transition Therapeutics (Transition Therapeutics) Cyclically Adjusted Price-to-FCF : (As of Jun. 17, 2024)

Transition Therapeutics Cyclically Adjusted Price-to-FCF Chart

Transition Therapeutics Annual Data
	Trend	Jun06	Jun07	Jun08	Jun09	Jun10	Jun11	Jun12	Jun13	Jun14	Jun15
Cyclically Adjusted Price-to-FCF		Get a 7-Day Free Trial					-	-	-	-	-

Transition Therapeutics Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Cyclically Adjusted Price-to-FCF	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Transition Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Transition Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transition Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transition Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Transition Therapeutics's Cyclically Adjusted Price-to-FCF falls into.

Transition Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Transition Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2016 is calculated as:

For example, Transition Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2016 was:

Current CPI (Mar. 2016) = 101.0535.

Transition Therapeutics Quarterly Data

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Transition Therapeutics  (NAS:TTHI) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.

Transition Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Transition Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Transition Therapeutics (Transition Therapeutics) Business Description